Why Spero Therapeutics, Inc.’s (SPRO) Stock Is Down 5.24%
As of Friday, October 02, Spero Therapeutics, Inc.’s SPRO share price has dipped by 5.24%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Commentary & Analysis
Why Spero Therapeutics, Inc.’s (SPRO) Stock Is Down 6.62%
As of Wednesday, September 23, Spero Therapeutics, Inc.’s SPRO share price has dipped by 6.62%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Spero Therapeutics, Inc.’s (SPRO) Stock Is Up 16.67%
As of Tuesday, September 22, Spero Therapeutics, Inc.’s SPRO share price has surged by 16.67%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Spero Therapeutics, Inc.’s (SPRO) Stock Is Up 18.60%
As of Tuesday, September 22, Spero Therapeutics, Inc.’s SPRO share price has surged by 18.60%, which has investors questioning if this is right time to sell.Tudor Pop
Why Spero Therapeutics, Inc.’s (SPRO) Stock Is Up 5.46%
As of Thursday, August 13, Spero Therapeutics, Inc.’s SPRO share price has surged by 5.46%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | SPRO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $69.3 | $250.1 | 18% |
|
| Shares Out (Mil) | 58.0 | 54.0 | 51% |
|
| Institutional Ownership | 86.4% | 93.1% | 54% |
|
| Float (Mil) | 47.1 | 41.4 | 45% |
|
| Beta | 1.48 | 0.95 | 82% |
|
| Avg Daily Volume (000s) | 1,374 | 661 | 75% |
|
| Price Change (52-week) |
(39.3%) | 49.5% | 23% |
|
| Growth | SPRO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 48.3% | 12.5% | 95% |
|
| Net Income (5yr) | 16.1% | (10.1%) | 66% |
|
| EPS (5yr) | 15.4% | 15.8% | 58 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.9%) | (15.7%) | 46% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | SPRO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $47 | $37 | 19% |
|
| Net Income (TTM) (Mil) | $7 | ($44) | 44% |
|
| EPS (TTM) | $0.130 | ($1.600) | 44% |
|
| Operating Cash Flow (TTM) (Mil) | $20 | ($33) | 41% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $22 | $175 | 12% |
|
| Valuation | SPRO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.57 | 2.36 | 43% |
|
| P/E | 9.3 | 18.9 | 15% |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | 0.6 | 1.0 | 31% |
|
| Ratios | SPRO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 56.3% | 67.3% | 69% |
|
| Net Margin | 15.7% | (74.8%) | 73% |
|
| ROA | 12.9% | (47.6%) | 91% |
|
| ROE | 19.2% | (54.9%) | 78% |
|
| Liabilities to Assets | 16.2% | 29.3% | 10% |
|
| F-Score | 8 | 3 | 93% |
|
Spero Therapeutics, Inc. did not pass any screens on 10/2/2026.
